BBA
AXSM icon

Baker Bros. Advisors’s Axsome Therapeutics AXSM Stock Holding History

Baker Bros. Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-610,970
Closed -$25.3M – 118
2022
Q1 		$25.3M Hold
610,970
– – 0.15% 46
2021
Q4 		$23.1M Buy
610,970
+71,913
+13% +$2.65M 0.11% 56
2021
Q3 		$17.8M Hold
539,057
– – 0.08% 66
2021
Q2 		$36.4M Sell
539,057
-89,357
-14% -$5.36M 0.16% 47
2021
Q1 		$35.6M Sell
628,414
-150,420
-19% -$10.6M 0.15% 52
2020
Q4 		$63.5M Sell
778,834
-180,923
-19% -$13.5M 0.24% 28
2020
Q3 		$68.4M Sell
959,757
-50,000
-5% -$3.9M 0.27% 23
2020
Q2 		$83.1M Buy
1,009,757
+120,000
+13% +$9.24M 0.37% 23
2020
Q1 		$52.3M Buy
889,757
+60,000
+7% +$4.89M 0.32% 26
2019
Q4 		$85.8M Buy
829,757
+57,471
+7% +$2.32M 0.46% 22
2019
Q3 		$15.6M Hold
772,286
– – 0.11% 42
2019
Q2 		$19.9M Sell
772,286
-427,714
-36% -$8.57M 0.14% 39
2019
Q1 		$17.1M Buy
+1,200,000
New +$11.1M 0.11% 39

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Baker Bros. Advisors's AXSM Position: Q2 2022 in Review

Baker Bros. Advisors sold out of Axsome Therapeutics (AXSM) in Q2 2022, closing a stake of 610,970 shares — an estimated $25.3M sold.

Baker Bros. Advisors first reported a position in AXSM in Q1 2019 and held it in 13 quarters. The position peaked at $85.8M in Q4 2019. 174 funds tracked by Wall St. Rank hold AXSM as of Q2 2022.

  • Baker Bros. Advisors reported no remaining Axsome Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Baker Bros. Advisors sold 610,970 Axsome Therapeutics shares in Q2 2022, an estimated $25.3M.
  • Baker Bros. Advisors first reported a position in Axsome Therapeutics in Q1 2019 and held it in 13 quarters.
  • Baker Bros. Advisors's Axsome Therapeutics position peaked at $85.8M in Q4 2019.
  • 174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2022.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.